GAROFALO ELIZABETH A. 4
4 · ACADIA PHARMACEUTICALS INC · Filed Jun 1, 2026
Research Summary
AI-generated summary of this filing
ACADIA (ACAD) Director Elizabeth Garofalo Exercises Options, Receives RSUs
What Happened
Elizabeth A. Garofalo, a director of ACADIA Pharmaceuticals (ACAD), recorded option exercise/conversion activity and receipt of restricted stock units (RSUs) in a Form 4 reporting transactions dated May 29, 2026. The filing shows an exercise/conversion involving 8,107 derivative shares and two awards totaling 25,315 RSUs (16,004 and 9,311). The exercise/conversion entries show an associated disposal of 8,107 shares at $0.00 (derivative), and the RSU awards are reported at $0.00 per share.
Key Details
- Filing date: 2026-06-01; transaction date(s): 2026-05-29.
- Derivative exercise/conversion (code M): 8,107 shares acquired; 8,107 shares disposed at $0.00.
- Awards/grants (code A): 16,004 RSUs and 9,311 RSUs granted/recorded (total 25,315 RSUs). Reported price: $0.00.
- Footnotes:
- F1: Each RSU represents a contingent right to receive one share of common stock.
- F2: The RSUs vested in full on May 29, 2026 (the issuer’s annual meeting).
- F3: Stock options referenced will vest quarterly over one year following grant (final tranche earlier of one year post-grant or next annual meeting).
- F4: The reporting person elected to defer receipt of the shares underlying the RSUs until the earliest of (i) the fifth anniversary of grant, (ii) 30 days after ceasing board service, or (iii) a change in control.
- Shares owned after the transaction: not specified in the provided filing details.
- No 10b5-1 plan or late-filing flag noted in the provided data.
Context
- The M-code entries indicate exercise or conversion of derivative securities (e.g., option exercise). The simultaneous disposal at $0.00 likely reflects a non-cash settlement or internal withholding/settlement related to the exercise as reported (the filing does not provide additional detail).
- The RSU awards vested on the annual meeting date, but the director has elected to defer receipt of the underlying shares under the plan’s deferral rules, so immediate share transfers to the director may be delayed.
- These filings are informational about insider compensation and exercises; they do not, by themselves, indicate the director’s market view. Purchases are generally more directly interpreted as a bullish signal than awards or option exercises.
Insider Transaction Report
Form 4
GAROFALO ELIZABETH A.
Director
Transactions
- Exercise/Conversion
Common Stock
[F1]2026-05-29+8,107→ 33,489 total - Exercise/Conversion
Restricted Stock Units
[F1][F2]2026-05-29−8,107→ 0 total→ Common Stock (8,107 underlying) - Award
Director Stock Options (Right to Buy)
[F3]2026-05-29+16,004→ 16,004 totalExercise: $21.66Exp: 2036-05-28→ Common Stock (16,004 underlying) - Award
Restricted Stock Units
[F1][F4]2026-05-29+9,311→ 9,311 total→ Common Stock (9,311 underlying)
Footnotes (4)
- [F1]Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
- [F2]The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held.
- [F3]The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders.
- [F4]The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. The reporting person has elected to defer receipt of the shares of common stock underlying the restricted stock units until the earliest of the following: (i) the fifth anniversary of the date of grant of such restricted stock unit award; (ii) the date that is 30 days following the date on which the director ceases to serve as a member of the board of directors of the Issuer or otherwise provide services to the Issuer; and (iii) a change in control of the Issuer as defined in the Issuer's 2024 Equity Incentive Plan, as amended.
Signature
/s/ Jennifer J. Rhodes, Attorney-in-Fact|2026-06-01